Drug Information

Drug (ID: DG00543) and It's Reported Resistant Information

• Name: Loncastuximab tesirine
• Synonyms: Loncastuximab tesirine; loncastuximab tesirine-lpyl
• Indication:
  In total 1 Indication(s)
  Diffuse large B-cell lymphoma [ICD-11: 2A81]; Approved; [1]
• Target: Loncastuximab tesirine; CD19_HUMAN; [1]
• DrugBank ID: DB16222

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Diffuse large B-cell lymphoma [ICD-11: 2A81]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: B-lymphocyte antigen CD19 (CD19) [1]

• Molecule Alteration: Expression; Up-regulation
• Sensitive Disease: Relapsed/refractory large B-cell lymphoma [ICD-11: 2A81.1]
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: Cell apoptosis; Inhibition; hsa04210
• Cell Pathway Regulation: Cell invasion; Activation; hsa05200
• Cell Pathway Regulation: Cell viability; Activation; hsa05200
• In Vitro Model: VL51 cells; Lymph; Homo sapiens (Human); CVCL_3169
• Experiment for Molecule Alteration: Flow Cytometry and protein analyses
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: The resistant cells had higher CD19 expression on their cell surface, which gave a much higher activity to the CD19 targeting antibody drug conjugate loncastuximab tesirine.

References

• Ref 1: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia Leukemia. 2019 Apr;33(4):884-892. doi: 10.1038/s41375-018-0265-z. Epub 2018 Sep 28.